BACKGROUND. Approximately 35 percent of all cases of Down's syndrome in fetuses can be detected by measuring maternal serum alpha-fetoprotein during the second trimester in the general population of pregnant women. Recent case-control studies indicate that this detection rate could be approximately doubled by measuring serum levels of unconjugated estriol and chorionic gonadotropin, which are abnormally low and abnormally high, respectively, in women carrying fetuses affected by Down's syndrome. METHODS. We prospectively screened 25,207 women and adolescents in the second trimester of pregnancy and assigned each a risk of fetal Down's syndrome with an algorithm that took into account measurements of all three serum markers in combination with maternal age. On this basis, 1661 subjects (6.6 percent) were initially assigned a second-trimester risk of fetal Down's syndrome of at least 1 in 190, and 962 (3.8 percent) were offered amniocentesis for chromosomal analysis after verification of gestational age. Gestational age was determined on the basis of the first day of the last menstrual period or, when available, by ultrasonography. RESULTS. Among the 760 women and adolescents who chose amniocentesis, 20 cases of fetal Down's syndrome were detected, along with 7 other chromosomal disorders. There was 1 additional case of fetal Down's syndrome among the 202 women who chose not to have amniocentesis. The rate of detection of Down's syndrome was thus 58 percent (21 of 36 expected cases), and the frequency of identifying a fetus with Down's syndrome in women undergoing amniocentesis was 1 per 38 amniocenteses (95 percent confidence interval, 1 in 25 to 1 in 62). CONCLUSIONS. Measuring serum alpha-fetoprotein, chorionic gonadotropin, and estriol is more effective in screening for fetal Down's syndrome than measuring maternal serum alpha-fetoprotein alone. Such an expanded protocol can readily be incorporated into existing prenatal screening programs.
Source Information
Foundation for Blood Research, Scarborough, Me. 04070-0190.
This article has been cited by other articles:
Mizejewski, G. J.
(2007). Physiology of Alpha-Fetoprotein as a Biomarker for Perinatal Distress: Relevance to Adverse Pregnancy Outcome. Exp. Biol. Med.
232: 993-1004
[Abstract][Full Text]
Berger, R. P., Dulani, T., Adelson, P. D., Leventhal, J. M., Richichi, R., Kochanek, P. M.
(2006). Identification of Inflicted Traumatic Brain Injury in Well-Appearing Infants Using Serum and Cerebrospinal Markers: A Possible Screening Tool. Pediatrics
117: 325-332
[Abstract][Full Text]
Philip, A. G.S., Wald, N. J.
(2004). Historical Perspectives: Maternal Serum Alpha-fetoprotein and Fetal Abnormalities. NeoReviews
5: e507-e510
[Full Text]
Liou, J.-D., Chu, D.-C., Cheng, P.-J., Chang, S.-D., Sun, C.-F., Wu, Y.-C., Liou, W.-Y., Chiu, D.T.Y.
(2004). Human Chromosome 21-Specific DNA Markers Are Useful in Prenatal Detection of Down Syndrome. Annals of Clinical & Laboratory Science
34: 319-323
[Abstract][Full Text]
Palomaki, G. E., Knight, G. J., Roberson, M. M., Cunningham, G. C., Lee, J. E., Strom, C. M., Pandian, R.
(2004). Invasive Trophoblast Antigen (Hyperglycosylated Human Chorionic Gonadotropin) in Second-Trimester Maternal Urine as a Marker for Down Syndrome: Preliminary Results of an Observational Study on Fresh Samples. Clin. Chem.
50: 182-189
[Abstract][Full Text]
Shimamura, A., de Oca, R. M., Svenson, J. L., Haining, N., Moreau, L. A., Nathan, D. G., D'Andrea, A. D.
(2002). A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood
100: 4649-4654
[Abstract][Full Text]
Herman, A., Dreazen, E., Tovbin, J., Weinraub, Z., Bukovsky, Y., Maymon, R.
(2002). Comparison between disclosure and non-disclosure approaches for trisomy 21 screening tests. Hum Reprod
17: 1358-1362
[Abstract][Full Text]
Wald, N., Members of the FASTER Trial Research Consortium, , Chasen, S. T., Skupski, D. W., Chervenak, F. A., McCullough, L. B.
(2002). First-Trimester Nuchal Translucency Screening. J Ultrasound Med
21: 481-487
[Full Text]
Perheentupa, A., Ruokonen, A., Tuomivaara, L., Ryynanen, M., Martikainen, H.
(2002). Maternal serum {beta}-HCG and {alpha}-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod
17: 794-797
[Abstract][Full Text]
Cassinat, B., Darsin, D., Guardiola, P., Toubert, M.-E., Rain, J.-D., Gluckman, E., Schlageter, M.-H.
(2001). Intermethod Discordance for {alpha}-Fetoprotein Measurements in Fanconi Anemia. Clin. Chem.
47: 1405-1409
[Abstract][Full Text]
Smith-Bindman, R., Hosmer, W., Feldstein, V. A., Deeks, J. J., Goldberg, J. D.
(2001). Second-Trimester Ultrasound to Detect Fetuses With Down Syndrome: A Meta-analysis. JAMA
285: 1044-1055
[Abstract][Full Text]
Reynolds, T M
(2000). Down's syndrome screening: a controversial test, with more controversy to come!. J. Clin. Pathol.
53: 893-898
[Abstract][Full Text]
Browner, C. H., Preloran, H. M.
(2000). Interpreting Low-Income Latinas' Amniocentesis Refusals. Hispanic Journal of Behavioral Sciences
22: 346-368
[Abstract]
Cassinat, B., Guardiola, P., Chevret, S., Schlageter, M.-H., Toubert, M.-E., Rain, J.-D., Gluckman, E.
(2000). Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia. Blood
96: 859-863
[Abstract][Full Text]
Howe, D. T, Gornall, R., Wellesley, D., Boyle, T., Barber, J.
(2000). Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans. BMJ
320: 606-610
[Abstract][Full Text]
Luthy, D. A.
(1999). Maternal Markers and Complications of Pregnancy. NEJM
341: 2085-2087
[Full Text]
Cole, L. A., Shahabi, S., Oz, U. A., Bahado-Singh, R. O., Mahoney, M. J.
(1999). Hyperglycosylated Human Chorionic Gonadotropin (Invasive Trophoblast Antigen) Immunoassay: A New Basis for Gestational Down Syndrome Screening. Clin. Chem.
45: 2109-2119
[Abstract][Full Text]
Goshen, R.
(1999). What factors regulate HCG production in Down's syndrome pregnancies?: Screening for Down's syndrome using HCG concentrations - a common practice but still and enigma. Mol Hum Reprod
5: 893-895
[Full Text]
Knofler, M.
(1999). What factors regulate HCG production in Down's syndrome pregnancies?: Regulation of HCG during normal gestation and in pregnancies affected by Down's syndrome. Mol Hum Reprod
5: 895-897
[Full Text]
Haddow, J. E., Palomaki, G. E., Allan, W. C., Williams, J. R., Knight, G. J., Gagnon, J., O'Heir, C. E., Mitchell, M. L., Hermos, R. J., Waisbren, S. E., Faix, J. D., Klein, R. Z.
(1999). Maternal Thyroid Deficiency during Pregnancy and Subsequent Neuropsychological Development of the Child. NEJM
341: 549-555
[Abstract][Full Text]
Permaul-Woods, J. A., Carroll, J. C., Reid, A. J., Woodward, C. A., Ryan, G., Domb, S., Arbitman, S., Fallis, B., Kilthei, J.
(1999). Going the distance: the influence of practice location on the Ontario Maternal Serum Screening Program. CMAJ
161: 381-385
[Abstract][Full Text]
Lam, Y. H., Yeung, W. S. B., Tang, M. H. Y., Ng, E. H. Y., So, W. W. K., Ho, P. C.
(1999). Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. Hum Reprod
14: 2120-2123
[Abstract][Full Text]
Haddow, J. E., Palomaki, G. E., Knight, G. J., Williams, J., Miller, W. A., Johnson, A.
(1998). Screening of Maternal Serum for Fetal Down's Syndrome in the First Trimester. NEJM
338: 955-962
[Abstract][Full Text]
Taipale, P., Hiilesmaa, V., Salonen, R., Ylostalo, P.
(1997). Increased Nuchal Translucency as a Marker for Fetal Chromosomal Defects. NEJM
337: 1654-1658
[Abstract][Full Text]
Seeds, J. W.
(1997). Ultrasonographic Screening for Fetal Aneuploidy. NEJM
337: 1689-1690
[Full Text]
Miell, J. P., Langford, K. S., Jones, J. S., Noble, P., Westwood, M., White, A., Nicolaides, K. H.
(1997). The Maternal Insulin-Like Growth Factor (IGF) and IGF-Binding Protein Response to Trisomic Pregnancy during the First Trimester: A Possible Diagnostic Tool for Trisomy 18 Pregnancies. J. Clin. Endocrinol. Metab.
82: 287-292
[Abstract][Full Text]
Wyllie, J. P, Madar, R J., Wright, M., Burn, J., Wren, C.
(1997). Strategies for antenatal detection of Down's syndrome. Arch. Dis. Child. Fetal Neonatal Ed.
76: 26F-30
[Abstract][Full Text]
Palomaki, G. E., Haddow, J. E., Beauregard, L. J.
(1996). Prenatal Screening for Down's Syndrome in Maine, 1980 to 1993. NEJM
334: 1409-1410
[Full Text]
Aitken, D. A., Wallace, E. M., Crossley, J. A., Swanston, I. A., van Pareren, Y., van Maarle, M., Groome, N. P., Macri, J. N., Connor, J. M.
(1996). Dimeric Inhibin A as a Marker for Down's Syndrome in Early Pregnancy. NEJM
334: 1231-1236
[Abstract][Full Text]
Mennuti, M.
(1996). A 35-Year-Old Pregnant Woman Considering Maternal Serum Screening and Amniocentesis. JAMA
275: 1440-1446
[Abstract]
Evans, M. I., O'Brien, J. E., Dvorin, E., Krivchenia, E. L., Drugan, A., Hume, R. F. Jr., Johnson, M. P.
(1996). Similarity of Insulin-Dependent Diabetics' and Non-Insulin-Dependent Diabetics' Levels of {beta}-hCG and Unconjugated Estriol With Controls: No Need to Adjust as With Alpha-Fetoprotein. Reproductive Sciences
3: 20-22
[Abstract]
Fletcher, J, Hicks, N R, Kay, J D S, Boyd, P A
(1995). Using decision analysis to compare policies for antenatal screening for Down's syndrome. BMJ
311: 351-356
[Abstract][Full Text]
Sailer, D. N. Jr, Lesser, K. B., Harrel, U., Rogers, B. B., Oyer, C. E.
(1995). The Clinical Utility of the Perinatal Autopsy. JAMA
273: 663-665
[Abstract]
Vyas, S
(1994). Screening for Down's syndrome. BMJ
309: 753-754
[Full Text]
Haddow, J. E., Palomaki, G. E., Knight, G. J., Cunningham, G. C., Lustig, L. S., Boyd, P. A.
(1994). Reducing the Need for Amniocentesis in Women 35 Years of Age or Older with Serum Markers for Screening. NEJM
330: 1114-1118
[Abstract][Full Text]
Pauker, S. P., Pauker, S. G.
(1994). Prenatal Diagnosis -- Why Is 35 a Magic Number?. NEJM
330: 1151-1152
[Full Text]
Golde, S. H., Hegge, F. N., Copel, J. A., Platt, L. D., Campbell, S., Haddow, J. E., Knight, G. J., Palomaki, G. E., Ewigman, B., Crane, J. P., Frigoletto, F.
(1994). Prenatal Ultrasound Screening and Perinatal Outcome. NEJM
330: 570-572
[Full Text]
Reynolds, T.M., Penney, M.D., Feudtner, C., Minnick, M. A., Fletcher, J. C., Wertz, D. C., D'Alton, M. E., DeCherney, A. H.
(1993). Prenatal Diagnosis. NEJM
328: 1710-1712
[Full Text]
D'Alton, M. E., DeCherney, A. H.
(1993). Prenatal Diagnosis. NEJM
328: 114-120
[Full Text]
Previous
